Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Earnings Data
Report Date
Feb 12, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.42Last Year’s EPS
1.05Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance in Q3 2025, with significant revenue growth and raised financial guidance for the year. The acquisition of Avadel Pharmaceuticals is positioned as a strategic move to enhance Alkermes' portfolio and market position. While there are concerns over increased R&D and SG&A expenses, the overall outlook remains positive with promising advancements in the orexin 2 receptor agonist portfolio.Company Guidance
Strong Third Quarter Performance
Alkermes delivered a strong third quarter with total revenues of $394.2 million and net sales of $317.4 million, reflecting a 16% year-over-year growth.
Raised Financial Guidance for 2025
The company raised its full-year 2025 guidance, expecting total revenues of $1.43 billion to $1.49 billion, GAAP net income of $230 million to $250 million, and adjusted EBITDA of $365 million to $385 million.
Acquisition of Avadel Pharmaceuticals
Alkermes announced the proposed acquisition of Avadel Pharmaceuticals to diversify its commercial portfolio and strengthen profitability, with the FDA-approved LUMRYZ expected to generate $265-$275 million in net revenue in 2025.
Proprietary Products Performance
VIVITROL net sales reached $121.1 million, ARISTADA $98.1 million, and LYBALVI $98.2 million, with LYBALVI showing 32% year-over-year growth.
Expansion of Orexin 2 Receptor Agonist Portfolio
The orexin 2 receptor agonist portfolio, led by alixorexton, is advancing rapidly with positive Phase II data for narcolepsy type 1 and plans for a global Phase III program.
ALKS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALKS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 28, 2025 | $29.72 | $31.00 | +4.31% |
Jul 29, 2025 | $26.15 | $27.00 | +3.25% |
May 01, 2025 | $28.77 | $30.58 | +6.29% |
Feb 12, 2025 | $31.96 | $33.50 | +4.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alkermes (ALKS) report earnings?
Alkermes (ALKS) is schdueled to report earning on Feb 12, 2026, Before Open (Confirmed).
What is Alkermes (ALKS) earnings time?
Alkermes (ALKS) earnings time is at Feb 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALKS EPS forecast?
ALKS EPS forecast for the fiscal quarter 2025 (Q4) is 0.42.